Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age

Authors:

Abstract
Hematopoietic cell transplantation (HCT) is an important treatment modality for hematologic cancers. Because of its medical complexity and high cost, disparities in utilization are well known.1-3 The Center for International Blood and Marrow Transplant Research (CIBMTR) is a national resource to assess HCT volume, but a denominator of patients with transplant-eligible diseases is required to examine utilization. Prior studies estimated the number of eligible cases by applying incidence rates from Surveillance Epidemiology and End Results (SEER) data to US census data to derive the denominator,2-4 with CIBMTR data providing the numerator of HCT volume.3-5 Alternatively, SEER Medicare data have been used to derive both the numerator and denominator, but this limits the study population to Medicare beneficiaries only.6A prior large CIBMTR study demonstrated significant increases in both volume and survival,1,2,5,7 but did not assess the impact of race, ethnicity, or age, nor did it determine if increases in volume or survival were equitable across these vulnerable subgroups.

This publication has 18 references indexed in Scilit: